Program
Alpha-PD1/IL2 Fusion Protein AWT020
Its studies are led by Anwita Biosciences.
Drug pageAlpha-PD1/IL2 Fusion Protein AWT020: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 1, since Oct 9, 20232 company-led studies, 2 open or runningNext primary completion: Jan 2029 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Anwita Biosciences | 22 open or running | phase 1since Oct 9, 2023 | Oct 9, 2023 | Jan 2029phase 1 · NCT07822919 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 9, 2023First study: phase 1 study in Advanced CancerFirst studyNCT06092580 · 60 planned · Australia
- Sep 2, 2026Phase 1 study in Advanced Cancers (Solid Tumors)NCT07822919 · 96 planned · United States
Ahead
- Jan 2029Primary completion: phase 1 study in Advanced Cancers (Solid Tumors)NCT07822919
TargetBeta
PDCD1 →read by rule
“A bifunctional fusion protein comprised of a monoclonal antibody directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) ”NCIt, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07822919Advanced Cancers (Solid Tumors) · United States | 1 | Recruiting | Jan 2029 | 96 |
| NCT06092580Advanced Cancer · Australia | 1 | Recruiting | Jun 30, 2026 | 60 |
How it is read
Names in the registry
- “AWT020”, 2 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.